CN

Company news

Location：

Home

News

Company news

Chairman Lv Xiangyang at↕γtended the 4th Financ✔↕ ‍ial Planner Festival of Man♥♦ ∞qian Technology and delivered a→♥ speech

Chairman Lv Xiangyang attended th→♥‌↑e 4th Financial Planner÷<π Festival of Manqian Technolo♥↕gy and delivered a speech

Categories:Company news
Author:
Origin:
Time of issue:2021-01-20
Views:0





Chairman Lv Xiangyang attended the 4th♣'↕ Financial Planner Festival of Manqian Technologyλλ<↕ and delivered a speech

(Summary description)On September 7, 2019,★‍ the 4th Financial Planner Festival hosted δγ by Manqian Technology was grandly held in S>•€ henzhen. Manqian Technology is the fir××♣st financial technology company to ₹≥propose the TAMP model in China, β¶←and it is an important part of t¥∏he financial investment sector of Youngy ↕γGroup.

Categories:Company news
Author:
Origin:
Time of issue:2021-01-20
Views:0

Information

On September 7, 2019, the 4th Financial Pl£∏anner Festival hosted by Ma≠φ✔₹nqian Technology was grandly held in Shenzhen‌≠←™. Manqian Technology is thα∏→&e first financial technology company to propose ¶↓®‌the TAMP model in China, and≥₽$← it is an important part of the financial investm φent sector of Youngy Group.

Scan the QR code to read on your phone

Previous: Forge ahead and promote resear✘£ch and development, group leaders →δ™come to REGENECORE to gu☆>ide the work

Next: Yu Aihua, member of the Standing∑•∞ Committee of Anhui ±←↕≤Provincial Party Committee and secret∑♦>÷ary of Hefei Municipal Party Committee, he↑λπld talks with Lv Xiangyan↔≥β₩g

Previous: Forge ahead and promote re∑₽‍©search and development, group leaders come to RE¥≠GENECORE to guide the work

Next: Yu Aihua, member of the Standing Committee o✔∞f Anhui Provincial Party×‍ Committee and secretar✘→₽y of Hefei Municipal Party Committee, held t&‌×alks with Lv Xiangyang

01-03

2025



Nanjing Rongjiekang RC1416 dual antibody h§βas obtained 2 clinical trial licenses again

Recently, Nanjing RegeneCore Biotech‌¶€nology Co., Ltd.'s RC♠↑↔1416 project has consecutπ♣ively obtained Investigation‌↔al New Drug (IND) approvals from the Nationa‍±$>l Medical Products A≥↕dministration's Center for Drug Eva≥₩luation (CDE) for indications of ★Ωatopic dermatitis (AD) and chronic obstructi∞∑>ve pulmonary disease (COPD). The expansion of€® ≥ these indications has furt ÷↓¥her diversified the clinical application scen®®arios of RC1416 injectio≤↕n, providing better treatment op§λπtions for more patients..

12-02

2024



融捷集團：競逐新賽道(dào)，勇攀生(shēng)命科(kē)技(jì)高(gāo)峰

近(jìn)日(rì)，南京博爾迪生物科技有限σ±公司發布的(de)一(yī)則招募中重度哮喘患者的(de)消息引人(ré☆π∏‌n)關注。原來(lái)，由融捷康自(zì)研的(de)國(guó)內(nèi)首個(gèσ✔)自(zì)免雙特異性納米抗體(tǐ)藥物↔λδ(wù)——RC1416注射液，正在全國(guó)數(shù)十家(ji¥>ā)知(zhī)名醫(yī)院開(kāi)展臨床研究。這(z≤ €hè)款雙抗藥品在藥效、安全性和(hé)成藥性等多(duō)重指 ₽标上(shàng)具有(yǒu)較好(hǎo)的(de)優勢，未來(lái)有(yǒu)望成≥®>為(wèi)中重度哮喘患者的(de)福音(yīn)。

11-26

2024



RC1416 injection, developed σ↓ by Nanjing RegeneCore Biotech Co.,Ltd, isλ ÷ currently undergoing a Phase Ib clinical study tλ←o "evaluate the safety, tolerab'±±ility, pharmacokinetics, pha♣∞±rmacodynamics, immunogenic ☆αity, and preliminary effectiveness of RC1416£&♠ injection in patients with moderate t ♣o severe asthma." The lead institution for✘δ this study is the China-Japan Friendship Hospi≥$tal in Beijing, and it is simultaneously ©§₩↔being conducted at dozens oε↔₩<f renowned hospitalsγ'£ across the country.

TEL：

025-58608860

Enterprise email：rjk@regenecore.com

WeChat cooperative consultation

www.300.cn nanjing 備案号：京ICP證000000号

You are the th visitor